Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Lead-212 PSV359 Therapy for Patients With Solid Tumors
NCT06710756 · View on ClinicalTrials.gov ↗
Study Summary
Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
Conditions Studied
Interventions
- DRUG [203Pb]Pb-PSV359
- DRUG [212Pb]Pb-PSV359
Study Locations (3)
Missouri
- Saint Louis University — St Louis
Nebraska
- Nebraska Cancer Specialists — Omaha
Pennsylvania
- University of Pittsburgh Medical Center — Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2025-04-28 |
| Est. Completion | 2032-05-28 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06710756
The ClinicalTrials.gov registry entry for NCT06710756 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Perspective Therapeutics, which has 34 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 8 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions — of which [203Pb]Pb-PSV359 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06710756 reports 3 study locations spanning 3 distinct geographic areas — top geographies include Missouri, Nebraska, Pennsylvania. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06710756 about?
NCT06710756 is a clinical study titled "Lead-212 PSV359 Therapy for Patients With Solid Tumors". Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
What is the current status of trial NCT06710756?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 112 participants. The study started on 2025-04-28. Estimated completion is 2032-05-28.
What conditions does trial NCT06710756 study?
This clinical trial studies the following conditions: Colorectal Cancer, Ovarian Cancer, Head and Neck Cancer, Gastric Cancer, Esophageal Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06710756?
The interventions under investigation include: [203Pb]Pb-PSV359 (DRUG), [212Pb]Pb-PSV359 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06710756?
This trial is sponsored by Perspective Therapeutics, which has 34 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06710756 being conducted?
This trial has 3 study locations across Missouri, Nebraska, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.